Precigen, Inc. is a dedicated discovery and clinical-stage biopharmaceutical company advancing gene and cell therapies. Co.'s proprietary technology platforms develops product candidates designed to target urgent and intractable diseases in its core therapeutic areas of immuno-oncology, autoimmune disorders and infectious diseases. It has developed a pipeline of therapies across multiple indications. Co. operates through two segments: Biopharmaceuticals and Exemplar. Biopharmaceuticals segment is primarily comprised of the Co.'s legal entities of Precigen and ActoBio, as well as royalty interests in therapeutics and therapeutic platforms from companies not controlled by the Co.. We show 20 historical shares outstanding datapoints in our PGEN shares outstanding history coverage, used to compute PGEN market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing PGEN market cap history over the course of time is important for investors
interested in comparing PGEN's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of PGEN versus a peer is one thing; comparing
PGEN market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like PGEN can fluctuate over the course of history.
With this page we aim to empower investors researching PGEN by allowing them to research the PGEN market cap history. |
Free PGEN Email Alerts:
Video: The Importance of Market Cap
